Merck & Co. Hold Rating: Impact of Patritumab Deruxtecan Withdrawal and Future Growth Uncertainties

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), retaining the price target of $99.00.

Terence Flynn has given his Hold rating due to a combination of factors affecting Merck & Company’s current position. A significant reason is the recent withdrawal of the FDA filing for the drug patritumab deruxtecan, intended for treating a specific type of lung cancer. This decision was influenced by new data from a Phase 3 trial that showed the drug did not achieve statistically significant overall survival results, which is a critical measure of a drug’s efficacy.
Additionally, while there are ongoing efforts to identify patient subgroups that might benefit from the drug and a broad development program for other cancer types, the financial impact on Merck is relatively minor. The projected sales from patritumab are expected to contribute less than 1% to the company’s total revenue by 2030. These factors combined suggest that while there is potential for future growth, the current uncertainties warrant a cautious approach, justifying the Hold rating.

In another report released on May 23, Citi also maintained a Hold rating on the stock with a $84.00 price target.

MRK’s price has also changed moderately for the past six months – from $101.640 to $76.400, which is a -24.83% drop .